Log In
Print this Print this

apaziquone (EOquin) (formerly EO9, Neoquin)

  Manage Alerts
Collapse Summary General Information
Company Spectrum Pharmaceuticals Inc.
DescriptionAnalog of mitomycin C that is reduced by intracellular reductases into active DNA-damaging moieties
Molecular Target DNA
Mechanism of ActionBreaks/crosslinks DNA
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationBladder cancer
Indication DetailsTreat bladder cancer; Treat non-muscle invasive bladder cancer (NMIBC); Treat recurrent superficial bladder cancer (SBC); Treat superficial bladder cancer (SBC)
Regulatory Designation U.S. - Special Protocol Assessment (Treat non-muscle invasive bladder cancer (NMIBC))
Partner Handok Inc.; Nippon Kayaku Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today